We are proud of our achievements and want to share our successes. You can find the latest information on our projects, publications and events here.

Filter by:

NEWS

October 9, 2020
Update regarding our Amyotrophic Lateral Sclerosis (ALS) study conducted at Sahlgrenska University Hospital in Gothenburg, Sweden
Our Phase IIa clinical trial evaluating the safety, tolerability and possible efficacy of subcutaneous injections of ILB® in ALS is finalized and has been reported to the Swedish Medical Products Agency. The results indicate that, for the variants of ALS and the given dose investigated in the study, ILB® seems to have beneficial clinical effects…
Read More
September 14, 2020
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
Viken – 14th September 2020 – A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial…
Read More
August 28, 2020
TIKOMED granted Orphan Medicinal Drug Designation for ILB® for the treatment of amyotrophic lateral sclerosis by the European Commission
Viken – 28th August 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to its lead drug candidate ILB® for the treatment of patients with amyotrophic lateral sclerosis (ALS) – a terminal, neurodegenerative disease where most patients die of respiratory muscle weakness in less than…
Read More
March 13, 2020
TIKOMED secures 5 M € funding for the clinical development of ILB™ and IBSOLVMIR®
Viken – 13th March 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that it has successfully completed a €5 million round of financing from current investors. The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and…
Read More
March 9, 2020
Locust Walk appointed Strategic and Business Development Advisor for the licensing process of ILB™
Viken – 9th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of Locust Walk (LW) as strategic advisor and business development representative for the licensing process of ILB™.   “We are very pleased to secure this new collaboration as we have already worked closely with Locust Walk over the…
Read More
June 14, 2019
Information regarding our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital
Since we get several questions about our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital, we want to provide the following information on behalf of the company: 1. The study is closed 2. We plan to report the study’s outcome as soon as the analysis of the study is completed in 2020. 3.…
Read More
February 8, 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB-program and the IBsolvMIR® program. TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB…
Read More

EVENTS